Publication | Closed Access

Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment

Drug TargetingPolymer-drug ConjugateOvarian Cancer TreatmentMedicineBetulinic AcidTumor TargetingAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyTumor BiologyOvarian Cancer